What is InMed Pharmaceuticals Inc.'s earnings per share (EPS)?

InMed Pharmaceuticals Inc. (INM) reported diluted earnings per share of -$3.12 for fiscal year 2026. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

InMed Pharmaceuticals Inc. (INM) Financials

INM

FY2026 annual

Revenue Not reported for FY2026

Net Income -$12.6M -53.9% YoY

EPS (Diluted) -$3.12 YoY not available

Operating Cash Flow -$8.6M -6.7% YoY

Market Cap $7.5M as of Oct 21, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2026

Price / Book 7.0x on $1.1M equity, Q4 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 21, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Jun 30, 2026 Reported Sep 29, 2026 Currency USD FYE June

Newest figures come from the S-4/A for FY2026, filed Sep 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INM SEC filings page.

This page shows InMed Pharmaceuticals Inc. (INM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI INM FY2026 2026-10-04

The latest figures show a cash-burning business whose balance sheet has become materially thinner and more leverage-sensitive.

Between FY2025 and FY2026, total assets contracted by 80.6% while liabilities declined only 8.9%, leaving much less asset support behind the obligations. That mismatch left FY2026 debt-to-equity at 1.8x and the current ratio at 1.4x, a markedly tighter structure than the prior year.

In FY2025, the cash-conversion gap was narrow: net loss was $8.2M against operating cash use of $8.1M, indicating that the accounting loss largely represented cash economics rather than mainly non-cash charges. FY2026 then widened the gap, with net loss reaching $12.6M while operating cash use was $8.6M.

Gross margin recovered from 23.9% in FY2024 to 34.5% in FY2025, but that improvement did not overcome the cost structure. In FY2025, selling, general and administrative expense plus research and development totaled $8.2M against revenue of $4.9M, while reported liquidity equaled 3.1 months of the latest annual operating outflow.

Financial Health Signals

Financial health score not available

InMed Pharmaceuticals Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

InMed Pharmaceuticals Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

InMed Pharmaceuticals Inc. reported a net loss of $12.6M while operations used $8.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EPS (Diluted)

-$1.43

QoQ-95.9%

InMed Pharmaceuticals Inc. earned -$1.43 per diluted share (EPS) in Q4 2026. Against the prior quarter it is down 95.9%.

Revenue

Not reported for Q4 2026.

EBITDA

Not reported for Q4 2026.

Net Income

Not reported for Q4 2026.

Cash & Balance Sheet

Cash & Debt

$2.2M

YoY-79.6%

QoQ-57.5%

5Y CAGR-21.5%

InMed Pharmaceuticals Inc. held $2.2M in cash as of Q4 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ+65.8%

InMed Pharmaceuticals Inc. had 5M shares outstanding in Q4 2026. Against the prior quarter it is up 65.8%.

Free Cash Flow

Not reported for Q4 2026.

Dividends Per Share

Not reported for Q4 2026.

Margins & Returns

None of these metrics is reported for Q4 2026.

Capital Allocation

None of these metrics is reported for Q4 2026.

INM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INM quarterly income statement

Metric	FY26S-4/A	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Revenue	N/A	$4.9M+7.5%	$4.6M+11.2%	$4.1M+279.6%	$1.1M-42.8%	$1.9M	N/A
Cost of Revenue	N/A	$3.2M-7.5%	$3.5M+28.0%	$2.7M+400.6%	$546K	N/A	N/A
Gross Profit	N/A	$1.7M+55.0%	$1.1M-21.5%	$1.4M+158.1%	$544K	N/A	N/A
R&D Expenses	$3.0M+7.3%	$2.8M-12.3%	$3.2M-13.8%	$3.7M-48.8%	$7.3M+36.4%	$5.3M-8.1%	$5.8M
SG&A Expenses	$6.7M+23.0%	$5.4M-6.6%	$5.8M-0.8%	$5.8M-14.8%	$6.9M+53.3%	$4.5M+38.8%	$3.2M
Operating Income	N/A	N/A	N/A	-$7.9M+57.3%	-$18.6M-82.3%	-$10.2M	N/A
EBITDA	N/A	N/A	N/A	-$7.7M+57.9%	-$18.4M-82.6%	-$10.1M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	-$360K	N/A
Income Tax	N/A	N/A	$7K-45.8%	$13K	N/A	N/A	N/A
Net Income	-$12.6M-53.9%	-$8.2M-6.3%	-$7.7M+3.4%	-$7.9M+57.3%	-$18.6M-82.3%	-$10.2M-14.1%	-$8.9M
EPS (Basic)	-$3.12+62.7%	-$8.36+58.5%	-$20.14-519.7%	-$3.25+90.2%	-$33.17+12.6%	-$37.96	N/A
EPS (Diluted)	-$3.12	-$8.36	-$20.14	-$3.25	-$33.17	-$37.96	N/A
Diluted Shares (Avg)	4M	975,895	381,053	2M	560,829	268,793-94.9%	5M

Metric	Q4'26S-4/A	Q3'26S-4	Q2'2610-Q	Q1'2610-Q	Q4'25S-4/A	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Revenue	N/A	N/A	$820K-26.2%	$1.1M-11.4%	$1.3M+1.7%	$1.3M+7.6%	$1.1M-10.4%	$1.3M+40.2%
Cost of Revenue	N/A	N/A	$636K-2.3%	$717K-7.0%	$728K-32.6%	$1.1M+23.0%	$651K-12.7%	$771K-2.1%
Gross Profit	N/A	N/A	$184K-60.0%	$403K-18.3%	$577K+23.7%	$176K-39.3%	$461K+42.2%	$493K+2222.8%
R&D Expenses	N/A	$1.0M+140.4%	$631K-29.6%	$582K-16.9%	$801K+21.5%	$425K-35.2%	$895K+46.8%	$700K-45.8%
SG&A Expenses	N/A	$1.7M+9.9%	$1.6M-5.7%	$1.5M+2.6%	$618K-64.9%	$1.6M+15.3%	$1.7M+26.0%	$1.5M+15.0%
Net Income	N/A	-$3.0M-39.9%	-$2.0M+21.2%	-$1.7M-2.9%	-$1.8M+7.7%	-$2.1M-23.1%	-$2.6M-74.2%	-$1.7M+33.9%
EPS (Basic)	-$1.43-232.6%	-$0.73+62.4%	-$0.51+86.0%	-$0.44+83.8%	-$0.43+88.3%	-$1.94+45.8%	-$3.64+1.9%	-$2.71+82.2%
EPS (Diluted)	-$1.43	-$0.73	-$0.51	-$0.44	-$0.43	-$1.94	-$3.64	-$2.71
Diluted Shares (Avg)	N/A	4M	4M	4M	N/A	1M	706,546	620,127

Not reported in any period shown, so not listed: Operating Income, EBITDA, Interest Expense, Income Tax.

INM Balance Sheet

INM quarterly balance sheet

Metric	FY26S-4/A	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Total Assets	$3.0M-80.6%	$15.6M+31.8%	$11.8M-16.2%	$14.1M+10.3%	$12.8M+30.7%	$9.8M+25.4%	$7.8M
Current Assets	$2.7M-79.2%	$12.9M+48.1%	$8.7M-23.3%	$11.3M+18.1%	$9.6M+14.6%	$8.4M+32.7%	$6.3M
Cash & Equivalents	$2.2M-79.6%	$10.7M+63.5%	$6.6M-26.3%	$8.9M+44.3%	$6.2M-16.1%	$7.4M+26.8%	$5.8M
Short-Term Investments	$40K-8.6%	$43K+0.7%	$43K-3.1%	$44K-0.9%	$45K-3.6%	$46K+9.6%	$42K
Inventory	N/A	$961K-22.8%	$1.2M-23.0%	$1.6M-35.1%	$2.5M	N/A	N/A
Accounts Receivable	N/A	$465K+31.8%	$353K+35.5%	$260K+195.8%	$88K+638.5%	$12K-73.7%	$45K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.0M-8.9%	$2.1M-18.0%	$2.6M+29.8%	$2.0M-45.6%	$3.7M+54.2%	$2.4M+25.0%	$1.9M
Current Liabilities	$2.0M+6.3%	$1.8M-6.7%	$2.0M-1.4%	$2.0M-39.7%	$3.3M+49.8%	$2.2M+32.2%	$1.7M
Non-Current Liabilities	$0-100.0%	$306K-52.6%	$645K+3931.9%	$16K-95.9%	$389K+105.8%	$189K-23.7%	$248K
Total Equity	$1.1M-92.0%	$13.4M+45.9%	$9.2M-23.9%	$12.1M+33.2%	$9.1M+23.1%	$7.4M+25.5%	$5.9M
Retained Earnings	-$130.2M-11.1%	-$117.2M-7.5%	-$109.1M-7.6%	-$101.4M-8.5%	-$93.5M-24.8%	-$74.9M-15.8%	-$64.6M

Metric	Q4'26S-4/A	Q3'26S-4	Q2'2610-Q	Q1'2610-Q	Q4'25S-4/A	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Total Assets	$3.0M-80.6%	$9.1M-1.6%	$11.2M+31.6%	$13.4M+27.7%	$15.6M+31.8%	$9.3M	$8.5M-44.3%	$10.5M-4.1%
Current Assets	$2.7M-79.2%	$6.9M+7.5%	$8.8M+60.7%	$10.8M+48.4%	$12.9M+48.1%	$6.4M	$5.5M-53.7%	$7.3M-12.2%
Cash & Equivalents	$2.2M-79.6%	$5.2M+10.2%	$7.0M+103.4%	$9.3M+67.1%	$10.7M+63.5%	$4.7M-38.4%	$3.4M-64.1%	$5.6M-17.1%
Short-Term Investments	$40K-8.6%	$42K+2.6%	$43K+4.6%	$43K-0.8%	$43K+0.7%	$41K	$41K-8.3%	$43K+0.6%
Inventory	N/A	N/A	$948K-14.1%	$891K-27.0%	$961K-22.8%	$814K	$1.1M+48.1%	$1.2M+7.7%
Accounts Receivable	N/A	N/A	$183K-30.3%	$343K+20.6%	$465K+31.8%	$368K	$263K-29.6%	$285K+71.7%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.0M-8.9%	$2.2M-0.7%	$1.6M-30.9%	$1.8M-14.5%	$2.1M-18.0%	$2.3M	$2.3M-6.6%	$2.1M-89.9%
Current Liabilities	$2.0M+6.3%	$2.2M+20.2%	$1.5M-17.4%	$1.6M+8.3%	$1.8M-6.7%	$1.8M	$1.8M+6.6%	$1.4M+7.2%
Non-Current Liabilities	$0-100.0%	$31K-92.7%	$124K-76.6%	$215K-66.0%	$306K-52.6%	$419K	$529K-34.1%	$634K-96.7%
Total Equity	$1.1M-92.0%	$6.9M-1.8%	$9.6M+55.1%	$11.6M+38.1%	$13.4M+45.9%	$7.0M-36.8%	$6.2M-51.6%	$8.4M+187.7%
Retained Earnings	-$130.2M-11.1%	-$124.0M-7.4%	-$121.0M-6.8%	-$119.0M-7.4%	-$117.2M-7.5%	-$115.4M	-$113.3M-7.5%	-$110.8M-6.6%

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

INM Cash Flow Statement

INM quarterly cash flow statement

Metric	FY26S-4/A	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Operating Cash Flow	-$8.6M-6.7%	-$8.1M-15.9%	-$7.0M+4.1%	-$7.3M+53.3%	-$15.6M-59.2%	-$9.8M-32.8%	-$7.4M
Depreciation & Amortization	$205K-3.6%	$213K-3.1%	$220K+8.6%	$202K+8.9%	$186K+53.6%	$121K+7.5%	$112K
Stock-Based Compensation	$107K-10.4%	$119K-13.4%	$138K-50.5%	$278K-60.1%	$698K+14.4%	$610K-38.6%	$994K
Capital Expenditures	N/A	$0-100.0%	$9K-94.2%	$160K+309.2%	$39K+2167.1%	$2K-95.9%	$43K
Free Cash Flow	N/A	-$8.1M-15.8%	-$7.0M+6.0%	-$7.4M+52.4%	-$15.6M-59.5%	-$9.8M-32.0%	-$7.4M
Investing Cash Flow	$0	$0+100.0%	-$9K+98.6%	-$662K+1.7%	-$673K-38914.4%	-$2K-100.0%	$3.8M
Financing Cash Flow	$94K-99.2%	$12.3M+163.7%	$4.7M-56.4%	$10.7M-29.1%	$15.1M+38.8%	$10.9M+35123.1%	-$31K

Metric	Q4'26S-4/A	Q3'26S-4	Q2'2610-Q	Q1'2610-Q	Q4'25S-4/A	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Operating Cash Flow	-$3.0M-40.4%	-$1.7M-2.1%	-$2.4M+5.0%	-$1.6M+12.0%	-$2.1M-105.1%	-$1.7M+14.2%	-$2.5M-35.4%	-$1.8M+16.0%
Depreciation & Amortization	$48K-8.3%	$52K0.0%	$53K0.0%	$53K-2.5%	$53K-3.7%	$52K-5.6%	$53K-3.7%	$55K-0.5%
Stock-Based Compensation	N/A	$39K-4.2%	$26K+10.4%	$20K-30.2%	N/A	$40K-26.9%	$23K+26.8%	$29K+15.0%
Investing Cash Flow	$0	N/A	N/A	N/A	$0	N/A	N/A	N/A
Financing Cash Flow	-$1-100.0%	$232K-92.1%	$0-100.0%	-$137K-116.4%	$8.2M+4644531.3%	$2.9M	$339K	$838K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

INM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INM quarterly financial ratios

Metric	FY26S-4/A	FY25S-4	FY24S-4	FY2310-K	FY2210-K	FY2110-K	FY2010-K
Gross Margin	N/A	34.5%+10.6pp	23.9%-10.0pp	33.9%-16.0pp	49.9%	N/A	N/A
Operating Margin	N/A	N/A	N/A	-192.2%	-1707.3%	-535.9%	N/A
Net Margin	N/A	-165.1%	-166.9%	-192.2%	-1707.3%	-535.9%	N/A
Return on Equity	-1168.4%-1107.7pp	-60.8%+22.6pp	-83.4%-17.6pp	-65.7%+139.1pp	-204.9%-66.6pp	-138.3%+13.7pp	-152.1%
Return on Assets	-414.5%-362.2pp	-52.4%+12.5pp	-64.9%-8.6pp	-56.3%+89.1pp	-145.4%-41.1pp	-104.3%+10.3pp	-114.6%
Current Ratio	1.37-5.6x	6.99+2.6x	4.41-1.3x	5.66+2.8x	2.89-0.9x	3.780.0x	3.77
Debt-to-Equity	1.82+1.7x	0.16-0.1x	0.28+0.1x	0.17-0.2x	0.41+0.1x	0.330.0x	0.33
Asset Turnover	N/A	0.32-0.1x	0.39+0.1x	0.29+0.2x	0.09-0.1x	0.19	N/A
FCF Margin	N/A	-163.9%	-152.1%	-180.0%	-1434.0%	-514.3%	N/A

Metric	Q4'26S-4/A	Q3'26S-4	Q2'2610-Q	Q1'2610-Q	Q4'25S-4/A	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q
Gross Margin	N/A	N/A	22.5%-19.0pp	36.0%-3.0pp	44.2%+7.9pp	13.9%-10.8pp	41.5%+15.3pp	39.0%+36.7pp
Net Margin	N/A	N/A	-247.3%	-154.2%	-137.1%	-168.1%	-231.6%	-132.7%
Return on Equity	N/A	-43.0%-12.8pp	-21.1%+20.5pp	-14.9%+5.1pp	-13.3%+7.7pp	-30.2%-14.7pp	-41.6%-30.1pp	-20.0%
Return on Assets	N/A	-32.5%-9.6pp	-18.1%+12.2pp	-12.9%+3.1pp	-11.5%+4.9pp	-22.9%	-30.3%-20.6pp	-16.0%+7.2pp
Current Ratio	1.37-5.6x	3.12-0.4x	5.94+2.9x	6.95+1.9x	6.99+2.6x	3.49	3.05-4.0x	5.07-1.1x
Debt-to-Equity	1.82+1.7x	0.330.0x	0.17-0.2x	0.15-0.1x	0.16-0.1x	0.32	0.38+0.2x	0.25
Asset Turnover	N/A	N/A	0.07-0.1x	0.080.0x	0.080.0x	0.14	0.130.0x	0.120.0x

Not reported in any period shown, so not listed: Operating Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
InMed Pharmaceuticals Inc. INM	FY2026	N/A	-$12.6M	N/A	$7.5M	—
Shuttle Pharmaceuticals Holdings, Inc. SHPH	FY2025	N/A	-$11.7M	N/A	$23.4M	—
Redhill Biopharma Ltd. RDHL	FY2025	$286K	-$429K	N/A	$4.5M	—
Sunshine Biopharma Inc. SBFM	FY2025	$36.3M	-$6.0M	-16.5%	$853K	59/100
PRF Technologies Ltd. PRFX	FY2025	$17K	-$5.0M	N/A	$2.5M	—
China Pharma Holdings, Inc. CPHI	FY2025	$4.1M	-$3.2M	-76.9%	$31.2M	39/100

Where InMed Pharmaceuticals Inc. Ranks

Frequently Asked Questions

Is InMed Pharmaceuticals Inc. profitable?

No, InMed Pharmaceuticals Inc. (INM) reported a net income of -$12.6M in fiscal year 2026.

What is InMed Pharmaceuticals Inc.'s return on equity (ROE)?

InMed Pharmaceuticals Inc. (INM) has a return on equity of -1168.4% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is InMed Pharmaceuticals Inc.'s operating cash flow?

InMed Pharmaceuticals Inc. (INM) recorded an outflow of $8.6M in operating cash flow during fiscal year 2026, representing cash used by core business activities.

What are InMed Pharmaceuticals Inc.'s total assets?

InMed Pharmaceuticals Inc. (INM) had $3.0M in total assets as of fiscal year 2026, including both current and long-term assets.

How much does InMed Pharmaceuticals Inc. spend on research and development?

InMed Pharmaceuticals Inc. (INM) invested $3.0M in research and development during fiscal year 2026.

How many shares does InMed Pharmaceuticals Inc. have outstanding?

InMed Pharmaceuticals Inc. (INM) had 5M shares outstanding as of fiscal year 2026.

What is InMed Pharmaceuticals Inc.'s current ratio?

InMed Pharmaceuticals Inc. (INM) had a current ratio of 1.37 as of fiscal year 2026, which is considered adequate.

What is InMed Pharmaceuticals Inc.'s debt-to-equity ratio?

InMed Pharmaceuticals Inc. (INM) had a debt-to-equity ratio of 1.82 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is InMed Pharmaceuticals Inc.'s return on assets (ROA)?

InMed Pharmaceuticals Inc. (INM) had a return on assets of -414.5% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is InMed Pharmaceuticals Inc.'s P/E ratio?

InMed Pharmaceuticals Inc. (INM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2026). The market capitalization is $7.5M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is InMed Pharmaceuticals Inc.'s price-to-sales ratio?

InMed Pharmaceuticals Inc. (INM) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $7.5M as of Oct 21, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does InMed Pharmaceuticals Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2026, InMed Pharmaceuticals Inc. (INM) held $2.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.6M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is InMed Pharmaceuticals Inc.'s Piotroski F-Score?

InMed Pharmaceuticals Inc. (INM) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are InMed Pharmaceuticals Inc.'s earnings high quality?

InMed Pharmaceuticals Inc. (INM) reported a net loss of $12.6M while operations used $8.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.